Important Notice for Pacira BioSciences, Inc. Shareholders
New York, NY – The Gross Law Firm, a leading securities fraud class action law firm, notifies shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX) that the firm has commenced an investigation into potential securities fraud. The investigation focuses on allegations that Pacira BioSciences may have issued materially misleading business information to the investing public.
Class Period and Eligibility
The investigation covers share purchases made during the period from January 1, 2023, to November 1, 2024. Eligible shareholders are encouraged to contact the firm to discuss their legal rights and potential appointment as lead plaintiff in this action.
Background
Pacira BioSciences is a specialty pharmaceutical company engaged in the clinical development, manufacturing, and commercialization of new therapeutics. The company’s flagship product, Exparel, is a non-opioid local anesthetic indicated for use in various surgical procedures. Pacira BioSciences reported strong financial results for several quarters, leading to significant stock price appreciation during the class period.
Allegations of Securities Fraud
However, on November 2, 2024, a short seller report accused Pacira BioSciences of overstating the clinical benefits of Exparel and manipulating data to inflate sales. The report also alleged that the company had engaged in questionable accounting practices, leading to inflated revenue and earnings.
Possible Impact on Shareholders
Shareholders who purchased Pacira BioSciences stock during the class period may have suffered significant losses as a result of the alleged securities fraud. The price of PCRX stock dropped sharply following the release of the short seller report, and continued to decline in the days that followed.
Global Implications
The allegations against Pacira BioSciences have broader implications for the biotech industry and the investing public. If the allegations are proven true, it may lead to increased scrutiny of other companies in the sector and calls for greater transparency and accountability. It could also undermine investor confidence in the biotech industry as a whole, potentially leading to a market correction.
Contact The Gross Law Firm
If you purchased shares of Pacira BioSciences during the class period and wish to discuss your legal rights, please contact The Gross Law Firm at 888-223-7176 or email [email protected]. You may also fill out the contact form on our website at www.grosslawfirm.com.
Conclusion
The Gross Law Firm is committed to protecting the rights of shareholders and recovering damages for those who have been harmed by securities fraud. If you believe you may be a victim of securities fraud related to Pacira BioSciences, please contact us today to discuss your legal options.
- Pacira BioSciences, Inc. is under investigation for potential securities fraud.
- The investigation covers share purchases made between January 1, 2023, and November 1, 2024.
- Allegations include overstating clinical benefits and manipulating data.
- Shareholders may have suffered significant losses as a result.
- Implications for the biotech industry and investor confidence.
- Contact The Gross Law Firm for more information.
